65 related articles for article (PubMed ID: 22678774)
1. Increases in bioavailability of poorly absorbed drug by acylcarnitine.
Tomita M; Doi N; Kimura A; Hayashi M
J Pharm Sci; 2012 Sep; 101(9):3511-7. PubMed ID: 22678774
[TBL] [Abstract][Full Text] [Related]
2. Effects of acylcarnitines on efflux transporting system in Caco-2 cell monolayers.
Tomita M; Doi N; Hayashi M
Eur J Drug Metab Pharmacokinet; 2010 Sep; 35(1-2):1-7. PubMed ID: 21495260
[TBL] [Abstract][Full Text] [Related]
3. Absorption enhancement effect of acylcarnitines through changes in tight junction protein in Caco-2 cell monolayers.
Doi N; Tomita M; Hayashi M
Drug Metab Pharmacokinet; 2011; 26(2):162-70. PubMed ID: 21206134
[TBL] [Abstract][Full Text] [Related]
4. Enhanced bioavailability of cefoxitin using palmitoyl L-carnitine. I. Enhancer activity in different intestinal regions.
Sutton SC; LeCluyse EL; Cammack L; Fix JA
Pharm Res; 1992 Feb; 9(2):191-4. PubMed ID: 1553340
[TBL] [Abstract][Full Text] [Related]
5. Improvement of intestinal absorption of P-glycoprotein substrate by D-tartaric acid.
Iida A; Tomita M; Idota Y; Takizawa Y; Hayashi M
Drug Metab Pharmacokinet; 2006 Oct; 21(5):424-8. PubMed ID: 17072096
[TBL] [Abstract][Full Text] [Related]
6. Human small intestinal and colonic tissue mounted in the Ussing chamber as a tool for characterizing the intestinal absorption of drugs.
Rozehnal V; Nakai D; Hoepner U; Fischer T; Kamiyama E; Takahashi M; Yasuda S; Mueller J
Eur J Pharm Sci; 2012 Aug; 46(5):367-73. PubMed ID: 22418036
[TBL] [Abstract][Full Text] [Related]
7. Excellent absorption enhancing characteristics of NO donors for improving the intestinal absorption of poorly absorbable compound compared with conventional absorption enhancers.
Fetih G; Habib F; Katsumi H; Okada N; Fujita T; Attia M; Yamamoto A
Drug Metab Pharmacokinet; 2006 Jun; 21(3):222-9. PubMed ID: 16858126
[TBL] [Abstract][Full Text] [Related]
8. Acylcarnitines: drug absorption-enhancing agents in the gastrointestinal tract.
Fix JA; Engle K; Porter PA; Leppert PS; Selk SJ; Gardner CR; Alexander J
Am J Physiol; 1986 Sep; 251(3 Pt 1):G332-40. PubMed ID: 2875654
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein is responsible for the poor intestinal absorption and low toxicity of oral aconitine: in vitro, in situ, in vivo and in silico studies.
Yang C; Zhang T; Li Z; Xu L; Liu F; Ruan J; Liu K; Zhang Z
Toxicol Appl Pharmacol; 2013 Dec; 273(3):561-8. PubMed ID: 24120885
[TBL] [Abstract][Full Text] [Related]
10. Oral bioavailability and intestinal secretion of amitriptyline: Role of P-glycoprotein?
Abaut AY; Chevanne F; Le Corre P
Int J Pharm; 2007 Feb; 330(1-2):121-8. PubMed ID: 17092666
[TBL] [Abstract][Full Text] [Related]
11. Enhanced bioavailability of cefoxitin using palmitoylcarnitine. II. Use of directly compressed tablet formulations in the rat and dog.
Sutton SC; LeCluyse EL; Engle K; Pipkin JD; Fix JA
Pharm Res; 1993 Oct; 10(10):1516-20. PubMed ID: 8272416
[TBL] [Abstract][Full Text] [Related]
12. Decrease in oral bioavailability of ciclosporin by intravenous pulse of methylprednisolone succinate in rats.
Konishi H; Sumi M; Shibata N; Takada K; Minouchi T; Yamaji A
J Pharm Pharmacol; 2004 Oct; 56(10):1259-66. PubMed ID: 15482640
[TBL] [Abstract][Full Text] [Related]
13. In situ and in vivo efficacy of peroral absorption enhancers in rats and correlation to in vitro mechanistic studies.
Sharma P; Varma MV; Chawla HP; Panchagnula R
Farmaco; 2005; 60(11-12):874-83. PubMed ID: 16243320
[TBL] [Abstract][Full Text] [Related]
14. Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin.
Cho YA; Lee W; Choi JS
Pharmazie; 2012 Feb; 67(2):124-30. PubMed ID: 22512082
[TBL] [Abstract][Full Text] [Related]
15. pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs: kinetic analysis of quinidine efflux in situ.
Varma MV; Panchagnula R
J Pharm Sci; 2005 Dec; 94(12):2632-43. PubMed ID: 16258992
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of intestinal absorption and mucosal toxicity using two promoters. II. Rat instillation and perfusion studies.
Maher S; Wang X; Bzik V; McClean S; Brayden DJ
Eur J Pharm Sci; 2009 Nov; 38(4):301-11. PubMed ID: 19664704
[TBL] [Abstract][Full Text] [Related]
17. Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability.
Cao X; Yu LX; Barbaciru C; Landowski CP; Shin HC; Gibbs S; Miller HA; Amidon GL; Sun D
Mol Pharm; 2005; 2(4):329-40. PubMed ID: 16053336
[TBL] [Abstract][Full Text] [Related]
18. Absorption-enhancing effects of sodium caprate and palmitoyl carnitine in rat and human colons.
Shimazaki T; Tomita M; Sadahiro S; Hayashi M; Awazu S
Dig Dis Sci; 1998 Mar; 43(3):641-5. PubMed ID: 9539662
[TBL] [Abstract][Full Text] [Related]
19. Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus.
Arima H; Yunomae K; Hirayama F; Uekama K
J Pharmacol Exp Ther; 2001 May; 297(2):547-55. PubMed ID: 11303042
[TBL] [Abstract][Full Text] [Related]
20. Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl.
Kharasch ED; Hoffer C; Altuntas TG; Whittington D
J Clin Pharmacol; 2004 Mar; 44(3):224-33. PubMed ID: 14973303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
